This significant gap in our knowledge will likely require the development of a tissue-targeted immunotherapeutic strategy that increases the frequency and function of antiviral CD4+ and CD8+ TRM cells within affected tissues, thereby clearing persistent virus reservoirs and alleviating symptoms of LC. Here, CD4 is linked to laryngotracheoesophageal cleft.